Enhancing quality of life in people with relapsing multiple sclerosis treated with cladribine tablets: a plain language summary of the 2-year CLARIFY-MS study

This Plain Language Summary of Publication article (PLSP) from Neurodivergent Disease Management, highlights that cladribine tablets improved health-related quality of life in people with relapsing multiple sclerosis during the 2-year CLARIFY-MS study. Participants who were new to MS therapies and those previously treated experienced similar benefits. Safety results matched earlier findings, with no cases of severe immune system compromise (grade 4 lymphocyte reduction).

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study’ and was published in Multiple Sclerosis Journal.

Visit Sage using the link to read the original article.